Current EUA approval requires all antibody tests to accurately identify at least 90% of positive cases (sensitivity) and 95% of negative cases (specificity). The Beckman Coulter, Access IgG COVID-19 antibody test has been approved by the FDA based on clinical data supporting a 96.8% sensitivity and 99.8% specificity, after 15 days from a positive PCR test.
